Medicare AdvantageReimbursementMedium impact
MA09.009y, Reimbursement for Radiopharmaceutical Agents
Independence Blue Cross·Nuclear Medicine, Radiology, Oncology·Claims & Billing
Effective date
Apr 1, 2025
We identified it
Jun 19, 2026
Summary
Policy MA09.009y establishes new reimbursement guidelines for radiopharmaceutical agents effective April 1, 2025. The billing team must review and implement updated coding and reimbursement procedures for radiopharmaceutical services under Medicare Advantage plans.
Action Required
By March 15, 2025: Billing team must obtain the complete policy text from the URL provided and identify all specific radiopharmaceutical CPT/HCPCS codes affected. Update billing system edits, fee schedules, and claim submission logic to reflect new reimbursement rules. Communicate any coding or documentation changes to providers and clinical staff. Test updated billing workflows before the April 1, 2025 effective date. NOTE: The policy content summary provided does not include specific affected codes—the full policy text must be reviewed to identify exact CPT codes (e.g., 78xxx series for nuclear medicine) and HCPCS J-codes for radiopharmaceuticals that are subject to the new reimbursement methodology.